Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05916430 · ClinicalTrials.gov registry record
Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement
A clinical trial of Autism and Infant Development, sponsored by Emory University.
- Recruiting
- Registry status
- 2,120
- Enrollment target
- 2
- Study locations
NCT05916430: Recruiting study of Autism and Infant Development, sponsored by Emory University.
NCT05916430 is a study of Autism and Infant Development that is actively recruiting participants, run by Emory University. The registered enrollment target is 2,120 participants, above the 163-participant average among 104 other Autism trials with a reported enrollment target (1201% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05916430, a study of Autism and Infant Development, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- 2,120 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this project is to measure the clinical utility of an objective and quantitative eye-tracking assay collected on a standalone, mobile investigational device to accurately screen 9-month-old infants for autism spectrum disorder and other actionable delays.
Primary Outcome
Diagnostic performance measured by sensitivity, specificity, area under the receiver operating characteristic curve, positive predictive value, and negative predictive value of the eye-tracking-based assays when compared with clinical reference standard diagnostic outcome of ASD or non-ASD.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST EarliPoint Investigational Device
Study Locations (2)
Georgia
- Children's Healthcare of Atlanta - Atlanta
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,120 participants |
| Start Date | 2023-02-02 |
| Est. Completion | 2027-12 |
What NCT05916430 shows while recruiting
NCT05916430 is an observational study that tracks outcomes without assigning an intervention. Its 2,120 participants enrollment target places it among the larger protocols in the corpus, above the 163-participant average among 104 other Autism trials with a reported enrollment target (1201% higher).
The record links to 2 conditions, with Autism appearing as the primary indexed condition, and to 1 intervention - of which EarliPoint Investigational Device is the first listed.
NCT05916430 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05916430 about?
NCT05916430 is a clinical study titled "Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement". The goal of this project is to measure the clinical utility of an objective and quantitative eye-tracking assay collected on a standalone, mobile investigational device to accurately screen 9-month-old infants for autism spectrum disorder and other actionable delays.
What is the current status of trial NCT05916430?
This trial is currently recruiting. The enrollment target is 2,120 participants. The study started on 2023-02-02. Estimated completion is 2027-12.
What conditions does trial NCT05916430 study?
This clinical trial studies the following conditions: Autism, Infant Development.
What interventions are being tested in trial NCT05916430?
The interventions under investigation include: EarliPoint Investigational Device (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05916430?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05916430 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05916430's enrollment target sits among peer trials
2,120 2nd of 104 the highest of 104 other Autism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD
RECRUITING · NA
-
Online Pivotal Response Treatment Training in Autism Spectrum Disorder
RECRUITING · NA
-
Cerebellum and Autism: Regional Specialization for Social and Executive Functions
RECRUITING · NA
-
Modified Pivotal Response Treatment for Insistence on Sameness in Autistic Youth
RECRUITING · NA
-
Examining the Effectiveness of the Early Start Denver Model in Community Programs Serving Young Autism
RECRUITING · NA
-
Optimizing Outcomes for Young Autistic Children
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05681624 · 2,124 participants · NA
Maternal Oxygen Supplementation for Intrauterine Resuscitation
- NCT07431281 · 2,130 participants · Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- NCT05967273 · 2,106 participants · NA
CirrhosisRx CDS System
- NCT05650658 · 2,136 participants · NA
Left vs Left Randomized Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI